Sharpsten, Lucie
Amgen (United States)
3 papers on CoChat
Most cited papers
- Verified
Cardiac myosin activation with omecamtiv mecarbil in systolic heart failure
Teerlink, J. R., Diaz, R., Felker, G. M., McMurray, J. J. V., Metra, M., Solomon, S. D., Adams, K. F., Anand, I., Arias-Mendoza, A., Biering-Sørensen, T., et al. (2021) · New England Journal of Medicine
Heart Failure Treatment and ManagementCardiomyopathy and Myosin Studies
Cited by 656
- Verified
A GIPR antagonist conjugated to GLP-1 analogues promotes weight loss with improved metabolic parameters in preclinical and phase 1 settings
Véniant, M. M., Lu, S.-C., Atangan, L., Komorowski, R., Stanislaus, S., Cheng, Y., Wu, B., Falsey, J. R., Hager, T., Thomas, V. A., et al. (2024) · Nature Metabolism
Pharmacology and Obesity TreatmentRegulation of Appetite and Obesity
Cited by 218
- Verified
A Phase 1, Randomized, Double-Blind, Placebo-Controlled Single and MultipleAscending Dose Study of AMG 133 in Subjects with Obesity
Strande, J. L., Kurra, V., Jeswani, R., Oberoi, R., Sharpsten, L., Neutel, J., Véniant, M. M., & Parnes, J. R. (2023) · Metabolism
Pharmacology and Obesity TreatmentDiabetes Treatment and Management
Cited by 7
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free